Propranolol Therapy for Infantile Hemangioma.
Loading...
Date
2013-03
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Context: There has been widespread interest surrounding the use of beta-blockers (i.e. propranolol, timolol, nadolol, acebutolol) in the
treatment of infantile hemangiomas (IH).
Objective: To review literature evaluating treatment of IH with propranolol.
Evidence Acquisition: We conducted a literature search on PubMed and investigated for case reports, case series, and controlled trials
by using search terms including “hemangioma” and “propranolol.”
Results: Data suggest that beta-blockers are efficacious in cutaneous, orbital, subglottic, and hepatic hemangiomas and assist in the
resolution of ulcerated hemangiomas. Improvement has also been documented in children with PHACE syndrome. Propranolol
produces favorable results in children who do not respond to steroids and with no long-term adverse effects. Propranolol should be
administered with caution due to rare but serious side effects including hypoglycemia, wheezing, hypotension, and bradycardia.
Additionally, recurrence of lesions following the cessation of treatment has been documented.
Conclusions: Although large-scale randomized controlled trials must be conducted in order to further evaluate the safety and the
possible role of propranolol in the treatment of IH, the reviewed literature suggests that propranolol carries promise as a potential
replacement for corticosteroids as first-line therapy or as a part of a multimodal approach.
Description
Keywords
Beta-blockers, Capillary hemangioma, Infants, PHACE association, Propranolol
Citation
Gunturi Nivedita, Ramgopal Sriram, Balagopal Subramanian, Scott Julius Xavier. Propranolol Therapy for Infantile Hemangioma. Indian Pediatrics. 2013 March; 50(3): 307-313.